Submitted:
18 June 2026
Posted:
23 June 2026
You are already at the latest version
Abstract
Keywords:
Introduction
Materials and Methods
Study Design and Participants
Participant Selection
Clinical and Geriatric Assessment
Finger-Ring Test Procedure and Classification
- Age ≥65 years
- Diagnosis of chronic kidney disease (CKD)
- Ability to cooperate with study assessments and procedures
- Provision of written informed consent
- Advanced dementia
- Active delirium
- Severe visual or hearing impairment that could interfere with participation in study assessments
- Neuromuscular disorders (e.g., amyotrophic lateral sclerosis, myopathy, peripheral neuropathy)
- Major acute illness (e.g., acute myocardial infarction, acute stroke, or sepsis)
- Metastatic cancer with an expected survival of less than 3 months
- Severe edema that could substantially affect anthropometric measurements
Muscle Mass Assessment and Definition of Sarcopenia
Statistical Analysis
Results
| Variable | Total | FR=0 | FR=1 | p-value |
|---|---|---|---|---|
| Age, median (IQR), years | 73 (69–79) | 74 (69–80) | 73 (69–77) | 0.554 |
| Female sex, n (%) | 47 (41.6) | 19 (30.6) | 28 (54.9) | 0.016 |
| BMI, median (IQR), kg/m² | 27.3 (23.6–31.2) | 24.6 (22.2–27.3) | 31.6 (28.1–35.4) | <0.001 |
| Low muscle mass, n (%) | 44 (39.3) | 32 (51.6) | 12 (24.0) | 0.005 |
| Right calf circumference, median (IQR), cm | 35.0 (32.0–37.5) | 32.0 (30.0–34.9) | 37.0 (35.8–40.0) | <0.001 |
| Left calf circumference, median (IQR), cm | 35.0 (32.0–37.9) | 32.0 (30.0–35.0) | 37.0 (35.5–40.0) | <0.001 |
| eGFR, median (IQR), mL/min/1.73 m² | 22.0 (11.0–38.0) | 28.0 (14.0–43.5) | 20.0 (11.0–33.0) | 0.381 |
| Serum albumin, median (IQR), g/L | 34.5 (30.2–39.0) | 34.0 (31.0–38.0) | 35.5 (30.0–40.2) | 0.335 |
| Dominant handgrip strength (men), median (IQR), kg | 23.3 (17.6–28.4) | 23.3 (17.6–27.1) | 23.6 (17.6–28.9) | 0.58 |
| Dominant handgrip strength (women), median (IQR), kg | 13.8 (9.0–18.2) | 10.4 (8.2–16.1) | 14.7 (10.2–18.7) | 0.22 |
| Gait speed, median (IQR), m/s | 0.81 (0.63–0.82) | 0.81 (0.42–0.85) | 0.81 (0.81–0.81) | 0.423 |
| Parameter | Total | FR=0 | FR=1 | p-value |
|---|---|---|---|---|
| Katz ADL, median (IQR) | 5 (4–6) | 5 (4–6) | 5 (5–6) | 0.781 |
| Lawton IADL, median (IQR) | 7 (4–8) | 8 (4–8) | 7 (5–8) | 0.509 |
| MNA-SF, median (IQR) | 11 (9–13) | 11 (8–12) | 12 (10–13) | 0.019 |
| Malnutrition risk (MNA-SF ≤11), n (%) | 58/111 (52.3) | 38/60 (63.3) | 20/51 (39.2) | 0.019 |
| GDS-SF, median (IQR) | 3 (2–5) | 3 (2–4) | 4 (2–6) | 0.143 |
| Depression (GDS-SF ≥5), n (%) | 33/111 (29.7) | 15/60 (25.0) | 18/51 (35.3) | 0.330 |
| FRAIL score, median (IQR) | 2 (1–3) | 2 (1–3) | 2 (1–3) | 0.452 |
| SARC-F score, median (IQR) | 4 (1–6) | 4 (1–6) | 5 (2–6) | 0.688 |
| Number of medications, median (IQR) | 7 (5–10) | 7 (5–9) | 8 (6–11) | 0.075 |
| Polypharmacy (≥5 medications), n (%) | 94/112 (83.9) | 50/62 (80.6) | 44/50 (88.0) | 0.427 |
| Sarcopenia distribution, % (None/Probable/Confirmed/Severe) | 4.5 / 56.4 / 10.0 / 29.1 (n=110) | 3.3 / 45.9 / 11.5 / 39.3 (n=61) | 6.1 / 69.4 / 8.2 / 16.3 (n=49) | 0.039 |
| History of falls (≥1), n (%) | 36/112 (32.1) | 18/62 (29.0) | 18/50 (36.0) | 0.561 |
| Dynapenia, n (%) | 102/113 (90.3) | 59/62 (95.2) | 43/51 (84.3) | 0.063 |



| Diagnostic Metric | Overall Sample | 95% CI / Subgroup Results |
|---|---|---|
| AUC | 0.643 | 0.554–0.732 |
| Sensitivity | 72.7% | 58.2–83.7 |
| Specificity | 55.9% | 44.1–67.1 |
| Positive Predictive Value | 51.6% | 39.4–63.6 |
| Negative Predictive Value | 76.0% | 62.6–85.7 |
| LR+ | 1,65 | 1.19–2.28 |
| LR− | 0.49 | 0.29–0.83 |
| Accuracy | 62.5% | 53.3–70.9 |
| Youden Index | 0.286 | — |
| BMI <25 kg/m² (n=39) | AUC 0.536 | Sensitivity 90.5% / Specificity 16.7% |
| BMI 25–30 kg/m² (n=37) | AUC 0.575 | Sensitivity 69.2% / Specificity 45.8% |
| BMI >30 kg/m² (n=36) | AUC 0.662 | Sensitivity 40.0% / Specificity 92.3% |
| Model / Variable | OR | 95% CI | p-value |
|---|---|---|---|
| Univariable analysis | |||
| Right calf circumference (cm) | 1.641 | 1.360–1.981 | <0.001 |
| BMI (kg/m²) | 1.436 | 1.255–1.642 | <0.001 |
| Preserved muscle mass | 3.118 | 1.397–6.959 | 0.006 |
| MNA-SF score | 1.232 | 1.053–1.441 | 0.009 |
| Male sex | 0.363 | 0.168–0.785 | 0.010 |
| Number of medications | 1.156 | 1.014–1.318 | 0.031 |
| Multivariable Model 1 | |||
| Preserved muscle mass | 2.654 | 0.904–7.794 | 0.076 |
| BMI (kg/m²) | 1.414 | 1.228–1.629 | <0.001 |
| Age (years) | 1.016 | 0.946–1.092 | 0.656 |
| Male sex | 0.591 | 0.204–1.708 | 0.331 |
| Multivariable Model 2 | |||
| Preserved muscle mass | 2.246 | 0.807–6.252 | 0.121 |
| BMI (kg/m²) | 1.427 | 1.231–1.654 | <0.001 |
| MNA-SF score | 0.996 | 0.810–1.225 | 0.970 |
| Multivariable Model 3 | |||
| Preserved muscle mass | 2.145 | 0.759–6.066 | 0.150 |
| BMI (kg/m²) | 1.453 | 1.242–1.700 | <0.001 |
| MNA-SF score | 0.968 | 0.784–1.195 | 0.763 |
| Number of medications | 0.990 | 0.817–1.201 | 0.920 |
| Model | AUC | LR Test p-value |
|---|---|---|
| Finger-ring test alone | 0.643 | — |
| Finger-ring test + MNA-SF | 0.674 | 0.127 |
| Finger-ring test + calf circumference | 0.701 | 0.019 |
| Finger-ring test + age + sex | 0.737 | 0.004 |
| Finger-ring test + MNA-SF + age + sex | 0.737 | 0.009 |
| Full model | 0.752 (optimism-corrected: 0.710) | 0.008 |
Discussion
Strengths of the Study
Limitations
Clinical Implications
References
- Sabatino A, Cuppari L, Stenvinkel P, Lindholm B, Avesani CM. Sarcopenia in chronic kidney disease: what have we learned so far? J Nephrol. 2021;34(4):1347-1372. [CrossRef]
- Duarte MP, Almeida LS, Neri SGR, Oliveira JS, Wilkinson TJ, Ribeiro HS, et al. Prevalence of sarcopenia in patients with chronic kidney disease: a global systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2024;15(2):501-512. doi:10.1002/jcsm.13425. [CrossRef]
- Song SH, Kim K, Kim SM. Sarcopenia in chronic kidney disease: from bench to bedside. Kidney Res Clin Pract. 2023;42(3):321-333.
- Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. [CrossRef]
- Tanaka T, Takahashi K, Akishita M, Tsuji T, Iijima K. “Yubi-wakka” (finger-ring) test: a practical self-screening method for sarcopenia, and a predictor of disability and mortality among Japanese community-dwelling older adults. Geriatr Gerontol Int. 2018;18(2):224-232. [CrossRef]
- Lawongsa K, Srisuwan P, Tejavanija S, Gesakomol K. Sensitivity and specificity of Yubi-wakka (finger-ring) screening method for sarcopenia among older Thai adults. Geriatr Gerontol Int. 2024;24(3):263-268. doi:10.1111/ggi.14787. [CrossRef]
- Watanabe D, Yoshimura Y, Yamada M, Motokawa K, Shirobe M, Yoshida Y, et al. Factors associated with sarcopenia screened by finger-circle test among middle-aged and older adults: a population-based cross-sectional study. Geriatr Gerontol Int. 2021;21(6):486-492.
- Kang SH, Kim JC, Cha RH, Kim HW, Han SY, Joo YS, et al. Impact of volume status on sarcopenia in non-dialysis chronic kidney disease patients. Sci Rep. 2022;12:22289.
- Bahat G, Tufan A, Tufan F, Kilic C, Akpinar TS, Kose M, et al. Cut-off points to identify sarcopenia according to European Working Group on Sarcopenia in Older People definition. Clin Nutr. 2016;35(6):1557-1563. doi:10.1016/j.clnu.2016.02.002. [CrossRef]
- Demler OV, Pencina MJ, D’Agostino RB Sr. Misuse of DeLong test to compare AUCs for nested models. Stat Med. 2012;31(23):2577-2587. [CrossRef]
- Chinoraso J, Phoocharoenpaiboon V, Yeekian C, Ongkanchana C. Effect of the finger-ring test, compared with the standard test, as a predictor of sarcopenia in older adult patients: a systematic review and meta-analysis. Geriatr Gerontol Int. 2025;25(6):730-737. [CrossRef]
- Rosa B, Valdiviesso R, Cunha-Rodrigues M, Oliveira A, Nascimento H, Moreira P, et al. The finger-ring test as an indicator of muscle mass estimated by dual-energy X-ray absorptiometry in an adult community-dwelling population. Eur J Clin Nutr. 2024;79(5):435-442.
- Piodena-Aportadera MRB, Lau S, Tan CN, Lim WS, Ding YY, Ng TP, et al. Yubi-wakka test for sarcopenia screening in the community: comparative agreement, diagnostic performance and validity with calf circumference measurements. J Frailty Aging. 2024;13(2):98-107. [CrossRef]
- Fujii H, Kodani E, Kaneko T, Watanabe K, Takemura Y, Takahashi K, et al. Sarcopenia and coexistent risk factors detected using the ‘Yubi-wakka’ (finger-ring) test in adults aged over 65 years in the public annual health check-up in Tama City, Tokyo: a cross-sectional study. BMJ Open. 2022;12(12):e061613.
- Chen TP, Kao HH, Ogawa W, Arai H, Tahapary DL, Assantachai P, et al. The Asia-Oceania consensus: definitions and diagnostic criteria for sarcopenic obesity. Obes Res Clin Pract. 2025;19(3):185-192. doi:10.1016/j.orcp.2025.05.001. [CrossRef]
- Lee BC, Lee J, Cho KH, Moon C. Association between the finger-ring test and quality of life in community-dwelling older women: cross-sectional study. BMC Geriatr. 2025;26(1):98. doi:10.1186/s12877-025-06908-3. [CrossRef]
- Lin YH, Lee KC, Tzeng YL, Chen HC, Hsu CC, Wang CY, et al. Comparison of four screening methods for sarcopenia among community-dwelling older adults: a diagnostic accuracy study. Geriatr Nurs. 2022;49:157-163.
- Li R, Hu X, Tan L, Zhang Y, Wang H, Liu Y, et al. Screening for sarcopenia with a self-reported cartoon questionnaire: combining SARC-F with finger-ring test. J Nutr Health Aging. 2020;24(10):1100-1106.
- Pérez-Torres A, González Garcia ME, San José-Valiente B, Fernández-Reyes MJ, Pérez-Rojas J, Molina P, et al. Protein-energy wasting syndrome in advanced chronic kidney disease: prevalence and specific clinical characteristics. Nefrologia. 2017;38(2):141-151.
- Huang YF, Liu SP, Muo CH, Hsu CY, Chen YC, Wu IW, et al. Male sex and ageing are independent risk factors for sarcopenia stage in patients with chronic kidney disease not yet on dialysis. J Cachexia Sarcopenia Muscle. 2024;15(6):2684-2692.
- Haraguchi M, Miyaaki H, Nakamura Y, Miuma S, Taura N, Shibata H, et al. Assessment of the association between dysphagia and sarcopenia among elderly patients with cirrhosis: usefulness of the finger-ring test. Arch Gerontol Geriatr. 2021;95:104430. [CrossRef]
- Lian R, Jiang G, Liu Q, Zhang H, Wang Y, Li X, et al. Validated tools for screening sarcopenia: a scoping review. J Am Med Dir Assoc. 2023;24(11):1645-1654.
- Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300-307.e2. [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).